Hedge Fund - OrbiMed Advisors

Orbimed Advisors is limiting exposure to Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after selling approximately 81,305 shares in one transaction at $320 a piece, according to a recent Form 4 filing...

Samuel Isaly's Orbimed Advisors is one of the largest hedge funds focused almost entirely on the healthcare sector. In a recent intervention on CNBC, Mr.

Sam Isaly’s Orbimed Advisors disclosed its position in Relypsa Inc (NASDAQ:RLYP), a company that recently conducted its IPO.

Sam Isaly's Orbimed Advisors focuses on healthcare investments, and it has now disclosed a change to its holdings of Response Biomedical Corp.

Samuel Isaly's hedge fund, Orbimed Advisors, decreased its stake in NxStage Medical, Inc. (NASDAQ:NXTM) to around 2.89 million shares, from 3.14 million held earlier.

Orbimed Advisors, a fund focused on the healthcare sector, led by Samuel Isaly, disclosed minutes ago purchasing 125,000 shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX).

Orbimed Advisors, Intercept Pharmaceuticals: Samuel Isaly and his hedge fund, Orbimed Advisors, is focused on healthcare stocks.

Orbimed Advisors, Intercept Pharmaceuticals: In a recent SEC filing, Samuel Isaly and his hedge fund, Orbimed Advisors, reported decreasing their holding in Intercept Pharmaceuticals Inc (NASDAQ:ICPT...

If you were to ask many investors, hedge funds are viewed as delayed, outdated investment vehicles of an era lost to time.